About Syneos Health (NASDAQ:SYNH)
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300
Debt
Debt-to-Equity Ratio0.98%
Current Ratio1.23%
Quick Ratio1.23%
Price-To-Earnings
Trailing P/E Ratio19.59
Forward P/E Ratio16.62
P/E Growth0.95
Sales & Book Value
Annual Sales$2.67 billion
Price / Sales1.47
Cash Flow$3.7938 per share
Price / Cash9.99
Book Value$28.97 per share
Price / Book1.31
Profitability
EPS (Most Recent Fiscal Year)$1.94
Net Income$-138,460,000.00
Net Margins-5.18%
Return on Equity10.78%
Return on Assets4.22%
Miscellaneous
Employees21,000
Outstanding Shares103,800,000
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health (NASDAQ:SYNH) issued its quarterly earnings results on Wednesday, February, 28th. The company reported $0.67 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.52 by $0.15. The business had revenue of $750.47 million for the quarter, compared to analyst estimates of $757.94 million. Syneos Health had a positive return on equity of 10.78% and a negative net margin of 5.18%. View Syneos Health's Earnings History.
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY18 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of $2.68-2.94 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.56. The company issued revenue guidance of $3.23-3.33 billion, compared to the consensus revenue estimate of $3.21 billion.Syneos Health also updated its Q1 guidance to $0.54-0.60 EPS.
What price target have analysts set for SYNH?
11 analysts have issued 12-month price targets for Syneos Health's stock. Their predictions range from $41.00 to $65.00. On average, they expect Syneos Health's stock price to reach $50.7778 in the next twelve months. View Analyst Ratings for Syneos Health.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY) and Eloxx Pharmaceuticals (ELOX).
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair MacDonald, CEO & Director (Age 48)
- Dr. Michael Gibertini Ph.D., Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
- Mr. Jason M. Meggs, Exec. VP, Interim CFO & Principal Accounting Officer (Age 42)
- Dr. Judith Ng-Cashin, Chief Scientific Officer
- Ms. Rachel Stahler, Chief Information Officer (Age 42)
Has Syneos Health been receiving favorable news coverage?
Media coverage about SYNH stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syneos Health earned a media sentiment score of 0.03 on Accern's scale. They also gave news stories about the company an impact score of 46.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $37.90.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $3.92 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.
How can I contact Syneos Health?
Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syneos Health (NASDAQ:SYNH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Syneos Health in the last 12 months. Their average twelve-month price target is $50.7778, suggesting that the stock has a possible upside of 33.98%. The high price target for SYNH is $65.00 and the low price target for SYNH is $41.00. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.73 | 2.70 | 2.60 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $50.7778 | $50.8750 | $49.8750 | $65.00 |
| Price Target Upside: | 33.98% upside | 21.42% upside | 20.76% upside | 18.29% upside |
Syneos Health (NASDAQ:SYNH) Consensus Price Target History
Syneos Health (NASDAQ:SYNH) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Syneos Health (NASDAQ:SYNH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syneos Health (NASDAQ SYNH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.57%
Syneos Health (NASDAQ SYNH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Christopher L Gaenzle | CAO | Sell | 1,470 | $41.00 | $60,270.00 | |  |
| 9/18/2017 | Alistair Macdonald | CEO | Sell | 2,348 | $54.60 | $128,200.80 | 99,453 | |
| 9/18/2017 | Christopher L Gaenzle | CAO | Sell | 4,682 | $54.56 | $255,449.92 | 60,579 | |
| 9/18/2017 | Gregory S Rush | CFO | Sell | 9,703 | $54.48 | $528,619.44 | 78,593 | |
| 9/1/2017 | Christopher L Gaenzle | CAO | Sell | 42,601 | $58.67 | $2,499,400.67 | 69,557 | |
| 9/1/2017 | Gregory S Rush | CFO | Sell | 88,739 | $58.99 | $5,234,713.61 | 149,301 | |
| 8/30/2017 | Gregory S Rush | CFO | Sell | 41,420 | $58.26 | $2,413,129.20 | 42,793 | |
| 8/17/2017 | Alistair Macdonald | CEO | Sell | 8,828 | $55.65 | $491,278.20 | 110,629 | |
| 7/3/2017 | Alistair Macdonald | CEO | Sell | 10,555 | $58.38 | $616,200.90 | 83,935 | |
| 6/30/2017 | Christopher L Gaenzle | CAO | Sell | 6,873 | $58.32 | $400,833.36 | 47,450 | |
| 5/1/2017 | Alistair Macdonald | CEO | Sell | 9,467 | $45.00 | $426,015.00 | 83,935 | |
| 4/3/2017 | Christopher L Gaenzle | CAO | Sell | 4,733 | $45.70 | $216,298.10 | 53,050 | |
| 3/3/2017 | Alistair Macdonald | CEO | Sell | 8,828 | $45.00 | $397,260.00 | 83,296 | |
| 1/20/2017 | Alistair Macdonald | CEO | Sell | 1,375 | $50.50 | $69,437.50 | 52,854 | |
| 1/20/2017 | Christopher L Gaenzle | CAO | Sell | 1,186 | $50.09 | $59,406.74 | 40,223 | |
| 1/19/2017 | Gregory S Rush | VP | Sell | 2,907 | $50.57 | $147,006.99 | 45,782 | |
| 1/5/2017 | Alistair Macdonald | CEO | Sell | 14,840 | $52.19 | $774,499.60 | 69,069 | |
| 9/30/2016 | Gregory S Rush | VP | Sell | 35,503 | $44.70 | $1,586,984.10 | 82,712 | |
| 9/27/2016 | D. Jamie Macdonald | CEO | Sell | 53,970 | $44.30 | $2,390,871.00 | 62,220 | |
| 9/26/2016 | Robert W Breckon | Director | Sell | 12,197 | $44.16 | $538,619.52 | 15,561 | |
| 9/19/2016 | David F Burgstahler | Director | Buy | 1,000 | $43.19 | $43,190.00 | 36,065 | |
| 9/14/2016 | Christopher L Gaenzle | CAO | Sell | 4,734 | $43.14 | $204,224.76 | 19,252 | |
| 8/17/2016 | Alistair Macdonald | COO | Sell | 8,828 | $43.80 | $386,666.40 | 63,057 | |
| 8/4/2016 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 2,554,409 | $42.06 | $107,438,442.54 | | |
| 8/4/2016 | Teachers Pension Plan Ontario | Director | Sell | 2,445,591 | $42.06 | $102,861,557.46 | | |
| 8/2/2016 | D. Jamie Macdonald | CEO | Sell | 31,279 | $43.00 | $1,344,997.00 | 107,488 | |
| 8/1/2016 | Robert W Breckon | Director | Sell | 108 | $42.00 | $4,536.00 | 7,961 | |
| 7/28/2016 | Gregory S Rush | VP | Sell | 4,066 | $45.23 | $183,905.18 | 22,165 | |
| 7/20/2016 | D. Jamie Macdonald | CEO | Sell | 100,593 | $43.00 | $4,325,499.00 | 105,795 | |
| 7/15/2016 | Gregory S Rush | CFO | Sell | 5,917 | $41.50 | $245,555.50 | 24,016 | |
| 7/11/2016 | Alistair Macdonald | COO | Sell | 9,468 | $40.19 | $380,518.92 | 28,144 | |
| 7/11/2016 | Christopher L Gaenzle | CAO | Sell | 21,918 | $40.20 | $881,103.60 | 33,530 | |
| 7/1/2016 | Gregory S Rush | CFO | Sell | 1,358 | $37.97 | $51,563.26 | 19,457 | |
| 7/1/2016 | Robert W Breckon | Director | Sell | 421 | $37.97 | $15,985.37 | 8,069 | |
| 6/15/2016 | Christopher L Gaenzle | CAO | Sell | 7,702 | $40.14 | $309,158.28 | 18,287 | |
| 6/6/2016 | Michael Gibertini | Insider | Sell | 213,966 | $43.11 | $9,224,074.26 | 200,998 | |
| 6/2/2016 | Robert W Breckon | Director | Sell | 11,691 | $43.53 | $508,909.23 | 19,710 | |
| 5/6/2016 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,087,054 | $45.12 | $184,407,876.48 | | |
| 5/6/2016 | Teachers Pension Plan Ontario | Director | Sell | 3,912,946 | $45.12 | $176,552,123.52 | | |
| 4/18/2016 | James T Ogle | Director | Sell | 114,806 | $50.00 | $5,740,300.00 | 293,192 | |
| 4/12/2016 | D. Jamie Macdonald | CEO | Sell | 94,675 | $48.00 | $4,544,400.00 | 138,398 | |
| 4/1/2016 | Michael Gibertini | Insider | Sell | 9,000 | $40.78 | $367,020.00 | 56,282 | |
| 3/1/2016 | Michael Gibertini | Insider | Sell | 9,000 | $39.85 | $358,650.00 | 56,282 | |
| 2/4/2016 | Robert W. Breckon | Director | Sell | 3,882 | $40.03 | $155,396.46 | 8,432 | |
| 2/1/2016 | Gregory S. Rush | CFO | Sell | 17,752 | $40.27 | $714,873.04 | 20,132 | |
| 2/1/2016 | Michael Gibertini | insider | Sell | 9,000 | $40.57 | $365,130.00 | 47,282 | |
| 1/4/2016 | Michael Gibertini | insider | Sell | 9,000 | $46.83 | $421,470.00 | 36,282 | |
| 12/31/2015 | Alistair Macdonald | COO | Sell | 159,599 | $47.46 | $7,574,568.54 | 8,699 | |
| 12/31/2015 | Christopher L. Gaenzle | CAO | Sell | 9,468 | $48.18 | $456,168.24 | 7,291 | |
| 12/31/2015 | Gregory S. Rush | CFO | Sell | 35,503 | $48.17 | $1,710,179.51 | 8,132 | |
| 12/29/2015 | James T. Ogle | Director | Sell | 9,717 | $50.06 | $486,433.02 | 183,386 | |
| 12/8/2015 | Christopher L. Gaenzle | CAO | Sell | 25,185 | $41.78 | $1,052,229.30 | 7,291 | |
| 12/8/2015 | Gregory S. Rush | CFO | Sell | 81,035 | $45.13 | $3,657,109.55 | 8,132 | |
| 12/7/2015 | Alistair Macdonald | COO | Sell | 42,959 | $44.63 | $1,917,260.17 | 55,681 | |
| 12/7/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,597,937 | $45.00 | $206,907,165.00 | | |
| 12/7/2015 | Teachers Pension Plan Ontario | Director | Sell | 4,402,063 | $45.00 | $198,092,835.00 | | |
| 12/1/2015 | Michael Gibertini | insider | Sell | 9,000 | $46.52 | $418,680.00 | 36,282 | |
| 11/2/2015 | Michael Gibertini | insider | Sell | 9,000 | $41.70 | $375,300.00 | 36,282 | |
| 9/28/2015 | Alistair Macdonald | COO | Sell | 44,522 | $39.93 | $1,777,763.46 | 55,681 | |
| 9/14/2015 | Gregory S. Rush | CFO | Sell | 32,426 | $45.06 | $1,461,115.56 | 8,132 | |
| 8/31/2015 | Christopher L. Gaenzle | CAO | Sell | 17,421 | $41.16 | $717,048.36 | 7,291 | |
| 8/31/2015 | James T Ogle | Director | Sell | 55,000 | $41.12 | $2,261,600.00 | 183,386 | |
| 8/17/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,029,168 | $44.00 | $177,283,392.00 | | |
| 8/17/2015 | Teachers Pension Plan Ontario | Director | Sell | 3,857,525 | $44.00 | $169,731,100.00 | | |
| 8/12/2015 | D. Jamie Macdonald | CEO | Sell | 57,021 | $44.00 | $2,508,924.00 | | |
| 8/12/2015 | Robert W Breckon | Director | Sell | 8,381 | $44.00 | $368,764.00 | | |
| 5/14/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 6,599,761 | $29.68 | $195,880,906.48 | | |
| 5/14/2015 | Teachers Pension Plan Ontario | Director | Sell | 6,318,607 | $29.68 | $187,536,255.76 | | |
| 5/7/2015 | Gregory S Rush | CFO | Sell | 12,455 | $29.68 | $369,664.40 | | |
| 5/7/2015 | Michael Gibertini | Insider | Sell | 50,000 | $29.68 | $1,484,000.00 | | |
| 5/7/2015 | Robert W Breckon | Director | Sell | 8,226 | $29.68 | $244,147.68 | | |
(Data available from 1/1/2013 forward)
Syneos Health (NASDAQ SYNH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Does Syneos Health Inc (NASDAQ:SYNH) Go Up With The Market?
finance.yahoo.com - April 21 at 9:03 AM |
 | Syneos Health (SYNH) Now Covered by Analysts at Mitsubishi UFJ Financial Group
www.americanbankingnews.com - April 20 at 10:24 AM |
 | Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9 ...
globenewswire.com - April 18 at 9:14 AM |
| Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9, 2018
finance.yahoo.com - April 17 at 5:07 PM |
| Syneos Health (SYNH) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 5:55 PM |
| Syneos Health (SYNH) Downgraded to C at TheStreet
www.americanbankingnews.com - April 14 at 4:13 PM |
| $770.78 Million in Sales Expected for Syneos Health Inc (SYNH) This Quarter
www.americanbankingnews.com - April 14 at 1:47 AM |
| Syneos Health (SYNH) Stock Rating Reaffirmed by Goldman Sachs
www.americanbankingnews.com - April 12 at 11:52 PM |
| Zacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Announce $0.53 EPS
www.americanbankingnews.com - April 12 at 11:14 PM |
| Critical Analysis: Syneos Health (SYNH) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - April 12 at 11:35 AM |
| Syneos Health Inc (SYNH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 7:35 PM |
 | TBJ Data Dance: Inside the Triangle M&A list
www.bizjournals.com - April 8 at 5:03 PM |
| Syneos Health (SYNH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:36 PM |
| Syneos Health (SYNH) Stock Rating Reaffirmed by Robert W. Baird
www.americanbankingnews.com - April 7 at 9:54 PM |
| Syneos Health (SYNH) Rating Increased to Buy at Jefferies Group
www.americanbankingnews.com - April 7 at 8:50 PM |
| Syneos Health (SYNH) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 2 at 11:25 PM |
| Syneos Health (SYNH) Lifted to B- at TheStreet
www.americanbankingnews.com - April 1 at 11:24 AM |
| Syneos Health (SYNH) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 10:36 PM |
| Syneos Health Inc (NASDAQ:SYNH): Time For A Financial Health Check
finance.yahoo.com - March 28 at 4:38 PM |
| Syneos Health Inc (SYNH) Expected to Announce Quarterly Sales of $767.82 Million
www.americanbankingnews.com - March 28 at 9:15 AM |
| Syneos Health Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution
finance.yahoo.com - March 27 at 9:35 AM |
| $0.53 Earnings Per Share Expected for Syneos Health Inc (SYNH) This Quarter
www.americanbankingnews.com - March 26 at 11:06 PM |
| Syneos Health (SYNH) and Capital Senior Living (CSU) Head to Head Survey
www.americanbankingnews.com - March 26 at 11:18 AM |
| Syneos Health Inc (SYNH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM |
| Syneos Health (SYNH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 14 at 10:52 AM |
| Zacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Post $0.53 Earnings Per Share
www.americanbankingnews.com - March 9 at 5:18 PM |
 | Syneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers Guidance - StreetInsider.com
www.streetinsider.com - March 2 at 5:20 PM |
| Syneos Health Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 5:20 PM |
| Syneos Health (SYNH) Given "Equal Weight" Rating at Barclays
www.americanbankingnews.com - March 1 at 6:36 PM |
| Syneos Health (SYNH) Price Target Raised to $55.00 at SunTrust Banks
www.americanbankingnews.com - March 1 at 12:54 PM |
| Syneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers Guidance
www.streetinsider.com - March 1 at 8:57 AM |
| Should You Buy Syneos Health Inc (NASDAQ:SYNH) Now?
finance.yahoo.com - March 1 at 8:57 AM |
| Syneos Health (SYNH) Releases Q1 Earnings Guidance
www.americanbankingnews.com - February 28 at 9:14 AM |
| Syneos Health (SYNH) Issues FY18 Earnings Guidance
www.americanbankingnews.com - February 28 at 9:14 AM |
| Syneos Health Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 28 at 9:08 AM |
| Syneos Health (SYNH) Price Target Cut to $46.00
www.americanbankingnews.com - February 26 at 1:30 PM |
| Syneos Health (SYNH) Upgraded to "Outperform" at Wells Fargo & Co
www.americanbankingnews.com - February 24 at 3:50 PM |
| Robert W. Baird Reiterates $50.00 Price Target for Syneos Health (SYNH)
www.americanbankingnews.com - February 23 at 2:30 PM |
 | Management turnover pressures Syneos Health, down 15%
seekingalpha.com - February 22 at 5:01 PM |
| Zacks: Analysts Anticipate Syneos Health Inc (SYNH) to Announce $0.56 EPS
www.americanbankingnews.com - February 21 at 1:28 AM |
| Syneos Health (SYNH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM |
| Q2 Holdings Inc (NYSE:QTWO): Financial Strength Analysis
finance.yahoo.com - February 14 at 9:21 AM |
| INC Research (SYNH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 13 at 11:50 AM |
 | A Good Quarter and an Earnings Beat: Why Is Canada Goose Holdings Inc. Down?
www.msn.com - February 12 at 9:18 AM |
| INC Research (SYNH) & Its Rivals Financial Analysis
www.americanbankingnews.com - February 11 at 3:21 PM |
| Syneos Health Names Lisa van Capelle Chief Human Resources Officer
finance.yahoo.com - February 8 at 4:14 PM |
| Analyzing INC Research (SYNH) & Its Competitors
www.americanbankingnews.com - February 7 at 9:52 AM |
| Head-To-Head Review: INC Research (SYNH) and The Competition
www.americanbankingnews.com - February 6 at 1:28 PM |
| INC Research Holdings Inc (SYNH) Expected to Announce Quarterly Sales of $756.76 Million
www.americanbankingnews.com - February 6 at 11:28 AM |
| When It Comes to Artificial Intelligence in Healthcare, Patients Fear the Replacement of Doctors, Yet Are Open to AI Nurse Support
finance.yahoo.com - February 6 at 9:18 AM |
Syneos Health (NASDAQ:SYNH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Syneos Health (NASDAQ:SYNH) Income Statement, Balance Sheet and Cash Flow Statement
Syneos Health (NASDAQ SYNH) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
